The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 5, pp. 764-768. DOI 10.1345/aph.1A327
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milligan, P.
Right arrow Articles by Gage, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milligan, P.
Right arrow Articles by Gage, B.

Research Articles

Substitution of generic warfarin for Coumadin in an HMO setting

PE Milligan, GA Banet, AD Waterman, SK Gatchel, and BF Gage

BACKGROUND: Substitution of generic warfarin for Coumadin presents safety concerns due to warfarin's narrow therapeutic index and because a prior generic formulation was removed from the US market after it was associated with adverse events. OBJECTIVE: To determine whether a health maintenance organization (HMO) can add generic warfarin to its formulary without adversely affecting warfarin management or increasing adverse events. DESIGN: In a prospective, observational study, an HMO that formerly dispensed only Coumadin added a generic warfarin preparation (Barr Laboratories, Pomona, NY) to its formulary. SETTING: An anticoagulation service (ACS) affiliated with an HMO that was based in St. Louis, MO. PARTICIPANTS: The cohort consisted of 182 enrollees in the ACS as of May 1, 1999. At the start of the study, these participants were taking Coumadin; by October 31, 2000, all had switched to Barr warfarin. MEASUREMENTS AND MAIN RESULTS: We collected data 8 months prior to and 10 months after the introduction of generic warfarin for the following endpoints: international normalized ratio (INR) control, frequency of INR monitoring, number of dose changes, and rate of thrombotic and hemorrhagic events. Statistical process control charts were used to differentiate between random variation in the endpoints and changes due to different warfarin formulations, and we used the Wilcoxon signed-rank test to look for a change in any endpoint after patients changed to generic warfarin. No significant differences were found in any endpoint. CONCLUSIONS: Substitution of Barr warfarin for Coumadin did not significantly affect INR control, warfarin management, or adverse events. Our findings suggest that HMOs can safely substitute at least 1 generic formulation of warfarin without extra monitoring.


This article has been cited by other articles:


Home page
 Int J Qual Health CareHome page
R. Tennant, M. A. Mohammed, J. J. Coleman, and U. Martin
Monitoring patients using control charts: a systematic review
Int. J. Qual. Health Care, August 1, 2007; 19(4): 187 - 194.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster
Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression
Chest, May 1, 2006; 129(5): 1155 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Schulman
Care of Patients Receiving Long-Term Anticoagulant Therapy
N. Engl. J. Med., August 14, 2003; 349(7): 675 - 683.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.